Currently out of the existing stock ratings of Naureen Quibria, 11 are a BUY (100%).
Analyst Naureen Quibria, has had 10% of price targets met with an average potential upside of 44.52%, reached in 182 days on average. Previously, Naureen Quibria worked at CAPITAL ONE, MAXIM GROUP.
Naureen Quibria has documented 23 price targets and ratings displayed on 9 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on ADCT, ADC Therapeutics SA at 14-Sep-2023.
Analyst best performing recommendations are on CMRX (CHIMERIX).
The best stock recommendation documented was for CMRX (CHIMERIX) on 9/7/2022. The price target of $7 was fulfilled within 910 days with a profit of $4.83 (222.58%), with a performance score of 2.45.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 15-Sep-2026
$9
$7.92 (733.33%)
2 months 7 days ago
(15-Sep-2026)
0/3 (0%)
$7.66 (571.64%)
Buy Since 06-Sep-2024
$2
$0.92 (85.19%)
$8
5 months 19 days ago
(03-Jun-2026)
0/2 (0%)
$0.6 (42.86%)
Buy Since 22-Oct-2020
$10
$8.92 (825.93%)
$10
7 months 2 days ago
(20-Apr-2026)
0/10 (0%)
$8.22 (461.80%)
Buy Since 14-Apr-2025
$6
$4.92 (455.56%)
$10
8 months 28 days ago
(25-Feb-2026)
0/2 (0%)
$4.09 (214.14%)
Buy Since 08-Oct-2020
$10
1 years 11 months 9 days ago
(13-Dec-2024)
0/5 (0%)
$6.08 (155.10%)
Stocks Naureen Quibria covered previously. Scores are shown for active stocks only.
The record of these past calls is part of the data set at anachart.store.